Company: CRVO
Filing Date: 2025-04-29
Form Type: DEF 14A
Source: 0001437749-25-013543
Chunk: 73

Company: CervoMed Inc.
Filing Date: 2025-04-29
Form: DEF 14A
Chunk 73
---
 of common stock subject to any incentive award).

<div align='center'>38</div>

The committee at any time (including on or after the date of grant or following termination), in connection with a participant’s termination, may cause options or stock appreciation rights held by the participant to terminate, become or continue to become exercisable and/or remain exercisable, and restricted stock awards, RSUs, performance awards, stock bonuses or other stock-based awards then held by such participant to terminate, vest, settle or become free of restrictions and conditions to payment, as the case may be.

Dividend Equivalent Rights. Any participant selected by the committee may be granted dividend equivalents based on the dividends declared on shares of our common stock that are subject to any incentive award, to be credited as of dividend payment dates, during the period between the grant date of the incentive award and the date the incentive award is exercised, vests, is settled or expires, as determined by the committee. However, dividends or dividend equivalents will be paid out with respect to any incentive award only to the extent that the shares of common stock subject to the incentive award vest.

Term; Termination; Amendments. Unless terminated earlier, the 2025 Plan will terminate at midnight on the day before the 10 anniversary of the earlier of the date of the 2025 Plan’s adoption by the Board and the date of its approval by the stockholders. The Board may suspend or terminate the 2025 Plan or any portion of the 2025 Plan at any time. In addition to the committee’s authority to amend the 2025 Plan with respect to participants resident outside of the U.S. or employed by a non-U.S. subsidiary, the Board may amend the 2025 Plan from time to time in order that incentive awards under the 2025 Plan will conform to any change in applicable laws or regulations or in any other respect that the Board may deem to be in our best interests; provided, however, that no amendments to the 2025 Plan will be effective without stockholder approval, if it is required under Section 422 of the Code or the Listing Rules of Nasdaq (or other applicable exchange or market on which our common stock may be traded or quoted). Termination, suspension or amendment of the 2025 Plan will not adversely affect the rights of a participant under a previously granted incentive award without the consent of the affected participant, except for adjustments in the event of changes in our capitalization or a “change in control” of our Company.

Transferability. In general